We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OncoMed and Lilly Enter Clinical Supply Agreement
News

OncoMed and Lilly Enter Clinical Supply Agreement

OncoMed and Lilly Enter Clinical Supply Agreement
News

OncoMed and Lilly Enter Clinical Supply Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OncoMed and Lilly Enter Clinical Supply Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OncoMed Pharmaceuticals, Inc. has announced that it has entered into an agreement with Eli Lilly and Company. Demcizumab, OncoMed's anti-DLL4 antibody, is being tested in combination with Lilly's Alimta® (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC).

Under the terms of this agreement, Lilly will provide clinical supply of Alimta for OncoMed's ongoing Phase 2 DENALI trial.

"This agreement with Lilly strengthens our efforts to investigate demcizumab as a key component alongside Alimta and platinum chemotherapy for the initial treatment of locally advanced or metastatic non-squamous non-small cell lung cancer," said Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer. "These data will add to the growing body of research to determine whether certain three-drug combinations may help improve patient outcomes."

OncoMed initiated enrollment in the randomized Phase 2 DENALI trial in January 2015 to test the efficacy and safety of demcizumab in combination with Alimta and carboplatin. Alimta is approved as an initial treatment in combination with cisplatin for locally advanced or metastatic NSCLC for patients with non-squamous histology.

The DENALI trial is expected to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.

Advertisement